ArticleIrish journal of medical science2026
Immunohistochemical investigation of transferrin receptor 2 (TFR2) immunoreactivity in patients with cutaneous lichen planus.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKROUND AND
aimLichen planus (LP) is a chronic inflammatory dermatosis with an unclear pathogenesis. Recent studies suggest that iron metabolism, oxidative stress, and ferroptosis mechanisms may play a role in the development of LP. Transferrin Receptor 2 (TFR2), an important receptor in iron homeostasis, may contribute to these processes.
methodsTFR2 immunoreactivity was evaluated using immunohistochemical methods on skin biopsies obtained from patients diagnosed with cutaneous LP (n = 45) and healthy controls (n = 30). Staining intensity was measured with QuPath image analysis software using 3,3'-diaminobenzidine (DAB). In addition, histopathological findings and staining localization were examined.
resultsIn healthy skin samples, TFR2 expression was limited, showing only weak staining in the basal epidermis and mild cytoplasmic positivity around the dermal vasculature (mean DAB intensity: 22.0% ± 5.5). In contrast, LP lesions exhibited pronounced epidermal irregularities, hyperkeratosis, inflammatory infiltration, and significantly increased TFR2 expression (mean DAB intensity: 57.0% ± 5.9; p < 0.05). Notably, strong cytoplasmic staining was observed in the epidermal basal layer and dermal inflammatory cells.
conclusionThis study demonstrated a significantly increased expression of TFR2 in LP lesions compared to healthy skin. The findings suggest that TFR2 may contribute to the pathogenesis of LP through the ferroptosis mechanism mediated by oxidative stress. However, further advanced studies evaluating specific markers related to ferroptosis are needed to better clarify this relationship.
Indexed as
Identifiers
41430519What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.